stockportfolio.pro
Stocks / DGX vs MRNA
DGX vs MRNA
Quest Diagnostics Incorporated and Moderna, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Quest Diagnostics Incorporated (DGX) | Moderna, Inc. (MRNA) | |
|---|---|---|
| Market cap | $22.4B | $20.7B |
| Revenue (latest FY) | $11.04B | $1.94B |
| Net income (latest FY) | $992.00M | $-2.82B |
| Revenue growth (5y CAGR) | 3.2% | 19.3% |
| Net margin | 9.0% | -145.2% |
| Return on equity | 13.8% | -32.6% |
| P/E ratio | 22.3 | — |
| Dividend yield | 1.7% | — |
| Profitable years (of last 10) | 10 | 2 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open DGX — free Open MRNA — freeFrequently asked questions
Which is bigger, DGX or MRNA?
Quest Diagnostics Incorporated is larger by market capitalization — $22.4B versus $20.7B.
Which grows faster, DGX or MRNA?
Over the last five fiscal years, Moderna, Inc. grew revenue faster — 19.3%/yr versus 3.2%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.